Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The fibrin polymerization interface represents the critical protein-protein interaction sites responsible for the assembly of fibrinogen into a structural fibrin network (Weisel & Litvinov, 2017). This process is initiated when thrombin cleaves fibrinopeptides A and B from fibrinogen, exposing N-terminal "knobs" (A and B) (Litvinov & Weisel, 2016). These knobs then bind to pre-existing "holes" ('a' and 'b') located in the C-terminal nodules of neighboring fibrin molecules (Mosesson, 2005). The A:a interaction is primarily responsible for the longitudinal growth of protofibrils, while the B:b interaction facilitates lateral association and branching (UniProt P02671). Dysregulation of this assembly process is a hallmark of thrombotic disorders, including deep vein thrombosis and ischemic stroke (StatPearls, 2023). As a therapeutic target, the interface offers a way to inhibit clot formation directly without necessarily inhibiting the enzymatic activity of thrombin or other coagulation factors. Experimental inhibitors, such as GPRP-based peptides, work by competitively occupying the 'a' holes, thereby preventing the formation of the fibrin mesh (PubMed PMID: 16102035). Targeting these specific interfaces is an active area of research for developing next-generation anticoagulants with potentially reduced bleeding risks.
Competitive inhibition of the "knob-hole" interactions between fibrin monomers, specifically blocking the binding of N-terminal "knobs" (exposed by thrombin cleavage) to the C-terminal "holes" in the gamma and beta nodules (Weisel & Litvinov, 2017).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibrin polymerization interface.